Sustained local drug delivery to the arterial wall via biodegradable microspheres.

This study was designed to evaluate the feasibility of applying locally delivered polylactic acid microspheres for drug delivery to the arterial wall. To study drug persistence, rhodamine-loaded microspheres were infused into one carotid artery of 14 rabbits and plain rhodamine solution into the other by using a porous balloon. To study tissue response, plain microspheres and dexamethasone-loaded microspheres were infused into the carotid arteries of another group of rabbits. To study the antiproliferative effects of locally delivered drug, 20 rabbits were subjected to overstretch balloon injury to both carotid arteries and divided into 4 groups: injury alone, plain microspheres, dexamethasone-loaded microspheres, and microspheres containing colchicine and dexamethasone. Fluorescent microspheres persisted in the vessel wall for 4 wk, whereas rhodamine without microspheres disappeared at 72 h. Histopathologic studies in arteries infused with unloaded microspheres showed inflammatory cell infiltrate with polymorphonuclear cells at 1 wk and macrophages and giant cells at 4 wk. Arteries infused with dexamethasone-loaded microspheres did not show any inflammatory cell infiltrate. Local delivery of dexamethasone or dexamethasone plus colchicine did not result in significant change in the intima-to-media ratio or in residual lumen following balloon injury. Polylactic acid microspheres may be used for prolonged delivery of drugs or other bioactive agents locally to the arterial wall. They induce an inflammatory reaction that is suppressable by dexamethasone in the microspheres. Dexamethasone or dexamethasone and colchicine delivered via this system, however, failed to reduce the degree of intimal hyperplasia after overstretch balloon injury to the rabbit carotid arteries.

[1]  A. Hickey,et al.  Biliary elimination of bromsulphthalein, phenolphthalein, and doxorubicin released from microspheres following intravenous administration , 1993, Biopharmaceutics & drug disposition.

[2]  D. Holmes,et al.  Restenosis: the clinical problem. , 1993, Coronary artery disease.

[3]  D. Faxon,et al.  Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. , 1993, Coronary artery disease.

[4]  M. Leon,et al.  New device angioplasty: the impact on restenosis. , 1993, Coronary artery disease.

[5]  E J Topol,et al.  The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. , 1992, Journal of the American College of Cardiology.

[6]  J. Isner,et al.  Percutaneous arterial gene transfer in a rabbit model. Efficiency in normal and balloon-dilated atherosclerotic arteries. , 1992, The Journal of clinical investigation.

[7]  K. Robinson,et al.  Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. , 1992, Journal of the American College of Cardiology.

[8]  J. O’Keefe,et al.  Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. , 1992, Journal of the American College of Cardiology.

[9]  P. Flandroy,et al.  Preparation of poly (D,L) lactide microspheres by emulsion-solvent evaporation, and their clinical applications as a convenient embolic material. , 1992, Journal of biomedical materials research.

[10]  R. Califf,et al.  Clinical trials of restenosis after coronary angioplasty. , 1991, Circulation.

[11]  I. Lancranjan,et al.  Parenteral depot-systems on the basis of biodegradable polyesters , 1991 .

[12]  E. Topol,et al.  Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions. , 1991, Journal of the American College of Cardiology.

[13]  M. Fishbein,et al.  A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. , 1991, Journal of the American College of Cardiology.

[14]  M. Savage,et al.  A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. , 1990, Circulation.

[15]  S. Thung,et al.  Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. , 1990, Journal of the American College of Cardiology.

[16]  G. Stone,et al.  A randomized trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty. , 1989, Catheterization and cardiovascular diagnosis.

[17]  J. Feijen,et al.  In vivo and in vitro degradation of glycine/DL-lactic acid copolymers. , 1989, Journal of biomedical materials research.

[18]  C. Pepine,et al.  Rationale for use of glucocorticoids in modification of restenosis after percutaneous transluminal coronary angioplasty. , 1987, The American journal of cardiology.

[19]  G E Visscher,et al.  Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. , 1985, Journal of biomedical materials research.

[20]  E. Braunwald,et al.  Mummification of the Infarcted Myocardium by High Dose Corticosteroids , 1978, Circulation.

[21]  A. Hickey,et al.  Manufacture and In-Vitro Assessment of Bromsulphthalein and Phenolphthalein Loaded Polyester Microspheres , 1994 .

[22]  T. Tice,et al.  Poly(lactide-co-glycolide) microcapsules for controlled release of steroids. , 1985, Methods in enzymology.

[23]  W. J. Larson,et al.  Degradation rates of polymers and copolymers of polylactic and polyglycolic acids. , 1974, Oral surgery, oral medicine, and oral pathology.

[24]  W. Cohn [13] The isolation and characterization of pseudouridine☆ , 1967 .